IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Acquired by Harvest Fund Management Co. Ltd

Harvest Fund Management Co. Ltd boosted its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 11.2% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,360 shares of the company's stock after purchasing an additional 541 shares during the period. Harvest Fund Management Co. Ltd's holdings in IDEXX Laboratories were worth $2,249,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also added to or reduced their stakes in the company. GAMMA Investing LLC raised its stake in shares of IDEXX Laboratories by 59,810.7% during the first quarter. GAMMA Investing LLC now owns 918,431 shares of the company's stock valued at $3,856,950,000 after acquiring an additional 916,898 shares in the last quarter. Principal Financial Group Inc. raised its stake in shares of IDEXX Laboratories by 58.3% during the first quarter. Principal Financial Group Inc. now owns 1,126,002 shares of the company's stock valued at $472,865,000 after acquiring an additional 414,802 shares in the last quarter. Alyeska Investment Group L.P. bought a new stake in shares of IDEXX Laboratories during the fourth quarter valued at approximately $156,412,000. BNP Paribas Financial Markets raised its stake in shares of IDEXX Laboratories by 221.3% during the fourth quarter. BNP Paribas Financial Markets now owns 441,319 shares of the company's stock valued at $182,459,000 after acquiring an additional 303,966 shares in the last quarter. Finally, Montrusco Bolton Investments Inc. bought a new stake in shares of IDEXX Laboratories during the first quarter valued at approximately $120,008,000. Institutional investors own 87.84% of the company's stock.

Analyst Ratings Changes

Several brokerages recently issued reports on IDXX. Leerink Partners lifted their price objective on shares of IDEXX Laboratories from $580.00 to $600.00 and gave the company an "outperform" rating in a report on Thursday, July 17th. Wall Street Zen raised shares of IDEXX Laboratories from a "hold" rating to a "buy" rating in a report on Saturday, July 12th. Stifel Nicolaus lifted their price objective on shares of IDEXX Laboratories from $510.00 to $540.00 and gave the company a "hold" rating in a report on Wednesday, July 2nd. Morgan Stanley lifted their price objective on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the company an "overweight" rating in a report on Monday, May 5th. Finally, Jefferies Financial Group began coverage on shares of IDEXX Laboratories in a report on Tuesday, July 1st. They set a "buy" rating and a $625.00 price objective on the stock. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $557.88.

IDEXX Laboratories Stock Up 0.2%

NASDAQ IDXX traded up $1.23 on Friday, hitting $535.54. The stock had a trading volume of 760,497 shares, compared to its average volume of 714,639. The business's fifty day moving average price is $530.62 and its 200 day moving average price is $470.66. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.16 and a quick ratio of 0.81. IDEXX Laboratories, Inc. has a 52-week low of $356.14 and a 52-week high of $579.47. The stock has a market cap of $43.07 billion, a price-to-earnings ratio of 49.50, a price-to-earnings-growth ratio of 4.07 and a beta of 1.54.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The company reported $2.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.93 by $0.03. IDEXX Laboratories had a net margin of 22.76% and a return on equity of 57.35%. The business had revenue of $998.43 million for the quarter, compared to analyst estimates of $998.25 million. During the same period in the previous year, the company earned $2.71 earnings per share. The business's revenue for the quarter was up 3.6% on a year-over-year basis. Equities research analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Insider Buying and Selling at IDEXX Laboratories

In other news, Director M Anne Szostak sold 1,260 shares of the business's stock in a transaction on Wednesday, May 21st. The shares were sold at an average price of $512.34, for a total transaction of $645,548.40. Following the sale, the director directly owned 1,801 shares of the company's stock, valued at $922,724.34. The trade was a 41.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.98% of the stock is owned by company insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.